Nebivololo E Idroclorotiazide Teva Italia (Hydrochlorothiazide, Nebivolol)

Nebivolol blocks β1‑adrenergic receptors in the heart, reducing heart rate and contractility. It also stimulates nitric‑oxide release, causing vasodilation. This dual action lowers cardiac output and peripheral resistance, contributing to blood‑pressure reduction.

The dosage is individualized by the prescribing clinician based on the patient’s blood‑pressure profile, renal function, and response to therapy. The prescriber determines the appropriate strength and frequency according to clinical guidelines.

Nebivolol and hydrochlorothiazide are generally not recommended during pregnancy unless the potential benefit outweighs the risk. Breastfeeding mothers should consult their healthcare provider, as the drugs may pass into milk and affect the infant.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑component agents, the nebivolol/hydrochlorothiazide combo offers both β‑blockade and diuretic effects in one tablet, simplifying regimens and potentially improving adherence. It may be preferred when a patient needs both heart‑rate control and volume reduction, whereas other classes like ACE inhibitors or calcium‑channel blockers work through different mechanisms.

Store the tablets at room temperature, below 25 °C, in the original container. Protect them from moisture and direct sunlight to maintain stability throughout the shelf life.

The medication is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless instructed otherwise.

Serious risks include severe hypotension, electrolyte disturbances such as low potassium, acute kidney injury, and rare allergic reactions. Patients should seek immediate medical attention if they experience fainting, muscle weakness, irregular heartbeat, severe swelling, or signs of an allergic response.

The product is contraindicated in patients with known hypersensitivity to nebivolol, hydrochlorothiazide, or any excipients, as well as those with severe renal impairment, uncontrolled electrolyte imbalances, or a history of severe hypotension. Clinicians should evaluate each patient’s medical history before prescribing.